Brand Name
Lampit
Generic Name
Nifurtimox
View Brand Information FDA approval date: October 01, 2020
Form: Tablet
What is Lampit (Nifurtimox)?
LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Phase III Randomized,Multicenter Non-inferiority Study to Evaluate the Efficacy and Safety of Shorter Benznidazole Regimens Compared to the Standard Regimen to Treat Adult Patients With Chronic Chagas Disease
Summary: Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of Latin America and affects people throughout the world. Currently treatment with the only two drugs effective against the infection, benznidazole and nifurtimox, has significant limitations including frequent adverse effects in adult patients. However, timely treatment is key to achieving global objectives of c...